Volume 30, Issue 175, September 2026

Neuroinflammation in Alzheimer's disease: current evidence and therapeutic targets - Part II

Izabela Ślusarczyk^♦, Szymon Uszak, Adrianna Chachuła, Natalia Kruk, Jan Olszewski, Julia Rojek, Wojciech Szlajss, Patrycja Jędrzejewska, Tomasz Szczawiński, Daria Wieczorek

Medical University of Lodz: Lodz, Łódź Voivodeship, Poland

^♦Corresponding author
Izabela Ślusarczyk, Medical University of Lodz: Lodz, Łódź Voivodeship, Poland

ABSTRACT

Alzheimer's disease is the most common form of dementia in the world, affecting tens of millions of people. Neuroinflammation is now known to be an important part of the process of Alzheimer's disease (AD) developing. In the past, it was thought of as a secondary byproduct of amyloid-beta (Aβ) plaque and tau neurofibrillary tangle accumulation, but it is now understood to be a central and early-acting pathological mechanism in AD progression. This review looks at how the brain and nervous system are affected by inflammation.

Keywords: neuroinflammation, Alzheimer's disease, microglia, cytokines, therapeutic targets

Medical Science, 2026, 30, e180ms3904

PDF

Published: 01 September 2026